Development of a patient-centric formulation of tegoprazan, a novel potassium-competitive acid blocker, using modified-release drug-coated pellets
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Su Chul | - |
dc.contributor.author | Kim, Myeongjoong | - |
dc.contributor.author | Kim, Donghyun | - |
dc.contributor.author | Jeon, Eun Kyung | - |
dc.contributor.author | Lee, Eun Hee | - |
dc.date.accessioned | 2022-10-06T06:42:30Z | - |
dc.date.available | 2022-10-06T06:42:30Z | - |
dc.date.created | 2022-10-06 | - |
dc.date.issued | 2022-09 | - |
dc.identifier.issn | 2093-5552 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/144089 | - |
dc.description.abstract | Purpose The purpose of this study was to develop a patient-centric formulation of tegoprazan, a novel potassium-competitive acid blocker, using modified-release drug-coated pellets. Methods Tegoprazan tablets, sustained-release (SR) polymer-coated pellets, SR drug-coated pellets, enteric-coated (DR) pellets, SR polymer-coated pellets with an enteric coating (CR1), SR drug-coated pellets with an enteric coating (CR2), and tegoprazan immediate-release (IR) powder were prepared. Dual-release capsules were prepared by combining the IR powder with the CR1, CR2, and DR pellets (IR/CR1, IR/CR2, and IR/DR, respectively). In vitro dissolution tests were conducted to screen the formulations, and in vivo pharmacokinetic (PK) analysis was conducted using cynomolgus monkeys. Design of experiments was employed to optimize the formulation for the CR2 pellets. The effect of the particle size on the dissolution profile of the CR2 pellets was investigated using scanning electron microscopy. Results In vitro dissolution of the IR/CR1 capsule produced the desired pH- and time-dependent release profile, and in vivo PK analysis confirmed that drug absorption was well-controlled by this formulation. The IR/CR2 capsule exhibited a pH- and time-dependent release of tegoprazan that was similar to that of the IR/CR1 capsule. Small drug particles appeared to become embedded in the densely packed coating, thus dissolving more slowly than the medium and large drug particles. Conclusion Unlike the CR1 pellets, the CR2 pellets did not require an additional coating and curing process. The developed IR/CR2 capsule is also expected to prevent nocturnal acid breakthrough and thus improve patient compliance. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGERNATURE | - |
dc.subject | RABEPRAZOLE EXTENDED-RELEASE | - |
dc.subject | PROTON PUMP INHIBITOR | - |
dc.subject | ESOMEPRAZOLE 40 MG | - |
dc.subject | DEXLANSOPRAZOLE MR | - |
dc.subject | POLYVINYL-ALCOHOL | - |
dc.subject | CLINICAL-TRIAL | - |
dc.subject | HEARTBURN | - |
dc.subject | PHARMACOKINETICS | - |
dc.subject | SECRETION | - |
dc.subject | TALC | - |
dc.title | Development of a patient-centric formulation of tegoprazan, a novel potassium-competitive acid blocker, using modified-release drug-coated pellets | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Eun Hee | - |
dc.identifier.doi | 10.1007/s40005-022-00582-y | - |
dc.identifier.scopusid | 2-s2.0-85135339945 | - |
dc.identifier.wosid | 000835566600001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF PHARMACEUTICAL INVESTIGATION, v.52, no.5, pp.623 - 638 | - |
dc.relation.isPartOf | JOURNAL OF PHARMACEUTICAL INVESTIGATION | - |
dc.citation.title | JOURNAL OF PHARMACEUTICAL INVESTIGATION | - |
dc.citation.volume | 52 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 623 | - |
dc.citation.endPage | 638 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002877220 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | CLINICAL-TRIAL | - |
dc.subject.keywordPlus | DEXLANSOPRAZOLE MR | - |
dc.subject.keywordPlus | ESOMEPRAZOLE 40 MG | - |
dc.subject.keywordPlus | HEARTBURN | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | POLYVINYL-ALCOHOL | - |
dc.subject.keywordPlus | PROTON PUMP INHIBITOR | - |
dc.subject.keywordPlus | RABEPRAZOLE EXTENDED-RELEASE | - |
dc.subject.keywordPlus | SECRETION | - |
dc.subject.keywordPlus | TALC | - |
dc.subject.keywordAuthor | Drug-coated pellet | - |
dc.subject.keywordAuthor | Modified release | - |
dc.subject.keywordAuthor | Multiparticulate drug delivery system | - |
dc.subject.keywordAuthor | Particle size | - |
dc.subject.keywordAuthor | Tegoprazan | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.